Future Directions and Unmet Needs in CLL/SLL Treatment

Video content above is prompted by the following:

The most significant chronic lymphocytic leukemia (CLL) treatment advances presented at ASCO focus on long-term follow-up data from key combination therapy trials, particularly the SEQUOIA and AMPLIFY studies. SEQUOIA arms C and D demonstrated sustained, durable responses with zanubrutinib monotherapy in high-risk patients with adverse cytogenetics, while the combination arms showed maintained efficacy and tolerability in TP53-mutated and 17p-deleted populations. These results represent major progress in addressing the most challenging CLL patient populations that historically had limited effective treatment options.

The future of CLL treatment lies in addressing remaining gaps in high-risk patient management and improving clinical trial design to better reflect real-world treatment decisions. Studies must better include and analyze outcomes in high-risk genetic populations, as overall response rates above 90% may mask suboptimal outcomes in specific patient subsets. Additionally, future trials should compare novel combinations against currently used standard therapies rather than outdated regimens, providing more clinically relevant comparative effectiveness data.

The greatest opportunity for advancing CLL care involves bridging the knowledge gap between cutting-edge research and community practice implementation. While academic centers readily adopt novel combination therapies based on emerging data, community practitioners may lack access to the latest trial updates and nuanced treatment selection guidance. Improving education and awareness about optimal treatment combinations for specific patient populations represents a critical unmet need that could significantly enhance CLL outcomes across all practice settings.